3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Biliary Tract Neoplasms
1
Interventions
Cisplatin
15
Gemcitabine
14
durvalumab
10
pembrolizumab
7
Oxaliplatin
6
Bevacizumab
6
Capecitabine
5
lenvatinib
4
Nivolumab
4
S 1 (combination)
3
Liquid Biopsy
3
Irinotecan
3
Folfox protocol
3
Fluorouracil
3
Carboplatin
3
zanidatamab
2
tremelimumab
2
envafolimab
2
Trastuzumab
2
Leucovorin
2
Injections
2
Blood Specimen Collection
2
Albumin-Bound Paclitaxel
2
trastuzumab deruxtecan
1
toripalimab
1
tislelizumab
1
poly ICLC
1
niraparib
1
neratinib
1
larotrectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Biliary Tract Neoplasms
×
gemcitabine-oxaliplatin regimen
×
90 days
×
Clear all
NCT05771480
2026-04-21
TOURMALINE
AstraZeneca
Phase 3
Active not recruiting
142 enrolled